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Abstract
BACKGROUND: Subtle decreases in platelet count may impede timely recognition of heparininduced thrombocytopenia (HIT), placing the patient at increased risk of thrombotic events.
OBJECTIVE: A clinical decision support system (CDSS) was developed to alert physicians
using computerized provider order entry when a patient with an active order for heparin
experienced platelet count decreases consistent with heparin induced thrombocytopenia (HIT).
METHODS: Comparisons for timeliness of HIT identification and treatment were evaluated for
the year preceding and year following implementation of the CDSS in patients with laboratory
confirmation of HIT. RESULTS: During the intervention time period, the CDSS alert occurred
41,922 times identifying 2,036 patients who had 2,338 inpatient admissions. The CDSS had no
significant impact on time from fall in platelet count to HIT laboratory testing(control 2.3 days
vs intervention 3.0 days p=0.30) and therapy(control 19.3 days vs intervention 15.0 days
p=0.45), and appeared to delay discontinuation of heparin products(control 1.3 days vs.
intervention 2.9 days p=0.04). However, discontinuation of heparin following shorter exposure
duration and after smaller decrease in platelet count occurred during the intervention period. The
HIT CDSS sensitivity and specificity were each 87% with a negative predictive value of 99.9%
and positive predictive value of 2.3%. CONCLUSIONS: Implementation of a CDSS did not
appear to improve the ability to detect and respond to potential HIT, but resulted in increased
laboratory testing and changes in clinician reactions to decreasing platelet counts that deserve
further study.
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Introduction
Heparin induced thrombocytopenia (HIT) is a clinicopathological syndrome associated with
significant morbidity and mortality [1]. The incidence of HIT ranges from 1-3% depending on
the type of heparin product and patient population [2, 3]. Criteria for the diagnosis of HIT in
patients treated with heparin products include either a significant proportional platelet count
decrease (for example, a 50% decrease from maximum value), or a decrease below a specified
threshold (for example, 150,000 platelets/mm3) [4-5]. The highest risk of developing HIT occurs
between 5 and 10 days of initial exposure to unfractionated (UFH) or low molecular weight
heparin (LMWH) [6-8]. Paradoxically, HIT is a disorder of thrombosis rather than bleeding [911]. The risk of developing a clinically significant thrombotic event within 30 days of diagnosis
of HIT has been estimated at 52.8% [12].

The prompt recognition of a proportional decrease in platelet count remains one of the challenges
of managing HIT. As Bates and Gawande observed, “monitoring is inherently boring and is not
performed well by humans” [13]. It is important to diagnose and initiate HIT treatment quickly
to prevent thrombotic complications. The lower the platelet nadir the more likely the patient will
develop a thrombosis [14, 15]. Various algorithms and recommendations have been developed
to help physicians in diagnosis of HIT; however, the challenge remains detecting a subtle fall in
platelet count that remains within ‘normal’ range [16, 17].

Computerized prescriber order entry (CPOE) systems provide opportunities to screen clinical
data based on predefined criteria to identify conditions and apply decision support [18-20].
While most CPOE systems provide basic safety features such as maximum dose checking and
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drug interaction screening, additional programming was performed to implement this clinical
decision support system (CDSS) to identify potential HIT. We hypothesized that incorporating
decision support algorithms into CPOE to alert clinicians of potential HIT would facilitate more
rapid diagnosis of HIT and initiation of treatment. We describe a novel CDSS to alert physicians
of the possibility of HIT. The objectives of this study were to assess the effectiveness of the
CDSS to identify potential HIT, improve timeliness of diagnosis and treatment of HIT, and
prevent clinical thrombotic events.

Methods
Study Design
This retrospective study was performed at Thomas Jefferson University Hospital (TJUH) a 728
bed tertiary care teaching hospital in Philadelphia. CPOE was initiated in 2001 and
implementation was completed throughout the hospital by 2003. At the time of this study, the
LastWord (Version 4.2.9 by GE Healthcare) CPOE system provided a self-documenting system
that recorded dates and times of medication, laboratory, radiology orders and procedures and
admission and discharge information as clinicians interacted with the system. The CDSS
program, written by developers at the hospital, screened a parallel data repository that mirrored
active orders and results once every 4 hours. When conditions specified by the CDSS were met,
the program generated an alert that appeared in the transactional CPOE application to any
clinician who accessed the identified patient record. The rule looked for the condition such that
in patients with an active order for heparin products the platelet count dropped during a three
week time period by 50%, or 30% if the absolute platelet count was less than 150,000
platelets/mm3. Although a trigger of 30% reduction in the absolute platelet count to below
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150,000 platelets/mm3 has not been extensively validated, we included this trigger to help
capture those with an absolute drop below 150,000 platelets/mm3. The recent 8th edition ACCP
guidelines concur that “there is no single definition of thrombocytopenia that meets all clinical
situations” (21). If either of these conditions occurred with an active order for a heparin product
a “pop-up” alert appeared suggesting the provider evaluate the patient for HIT. The alert
included the patient’s name, medical record number, baseline platelet count and date and most
recent platelet count and date (Figure 1). No patients were excluded on the basis of age, sex,
admitting diagnosis, service, type or dose of heparin product.

Patients were confirmed to have HIT if they had a positive 14C-serotonin release assay with
either a decrease in platelets by 50% or a decrease by 30% if the absolute platelet count was less
than 150,000 platelets/mm3 while on heparin (UFH or enoxaparin). Enoxaparin was the only
available LMWH at TJUH during the study period. The HIT antibodies by ELISA testing was
used to determine the time for HIT laboratory testing and not to confirm the diagnosis of HIT.
The control group was defined by identifying all patients described above during a 12-month
period preceding the implementation of the CDSS (March 2004 and March 2005). The
intervention period included patients admitted during a 12-month period following
implementation of the CDSS (September 2005 to September 2006) following a two-month
period to allow for clinician familiarity with the alert. This study was approved by the Thomas
Jefferson University Institutional Review Board. The requirement for informed consent was
waived.

6

HIT CDSS
Follow-up for Thrombosis
The records of patients with confirmed HIT were assessed for presence or absence of thrombotic
complications as documented by objective imaging reports during the 30 days following HIT
diagnosis; only thrombotic events occurring after the initiation of heparin products were
included. Duplex ultrasounds were required for diagnosis of extremity thromboses, thoracic
computed tomography (CT) or ventilation-perfusion scans for diagnosis of pulmonary embolism,
and head CT or magnetic resonance imaging (MRI) or angiography (MRA) defined stroke
diagnosis. Troponin levels and a documented clinical diagnosis in the medical record were used
to identify myocardial infarction.

Study End Points
Three primary parameters were evaluated before and after the implementation of the CDSS: time
from platelet count criterion to heparin product discontinuation, time from platelet count
criterion to HIT treatment initiation, and time from platelet count criterion to the first HIT
laboratory testing. The 14C-serotonin release assay was performed weekly at Jefferson Hospital
with the following specifications: low dose unfractionated heparin dilution 0.5 unit/mL, high
dose unfractionated heparin dilution 50 unit/mL, using single donor for fresh platelets.
HIT antibodies by ELISA testing (antibodies directed to the platelet factor 4-heparin complex)
were assessed by ASSERACHROM HPIA from Diagnostica Stago, Parsippany, NJ. Both ELISA
and 14C-serotonin release assay were ordered at the discretion of the clinician; there was no
reflex testing done by our laboratory for these conditions or results.
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Each parameter was assessed from the CDSS thresholds of platelet count decrease. We also
evaluated secondary outcomes of incidence of thrombotic events and the proportion of HIT
laboratory tests ordered. The time from heparin initiation to the alert was done to help us
evaluate the alert rules and determine if the time frame it was looking at was too long or short.
For example, if a patient was on heparin 2 days and had the alert, it may not be HIT. It was more
of an internal control to detect if the alert was actually finding HIT. The sensitivity, specificity,
positive and negative predictive values of the CDSS were calculated.

Statistical Analysis
Three time-to-event outcomes were compared before and after implementation of the CDSS
using the log-rank test. Proportional hazards regression was used to adjust these comparisons for
differences between groups in baseline covariates and assess potential effect modification and
confounding. The proportional hazards assumption was tested by including a log-time by
intervention group interaction term in the model. A variable was considered to be an effectmodifier if the p-value for the intervention group by variable interaction term was less than 0.15.
A variable was considered a confounder if the adjusted log hazard ratio differed from the
unadjusted log hazard ratio by +/- 15%. Hazard ratios were estimated from the proportional
hazards model with ratios greater than 1 indicating that the intervention group was more likely to
have an event.

Differences in the rates of thrombotic events and HIT assay tests were evaluated

using logistic regression. P-values were calculated for the test of the hypothesis that the odds
ratio = 1 (i.e., no difference). Due to the low incidence of thrombotic events, exact methods
were used to produce 95% confidence intervals and compute p-values. Sensitivity and
specificity were calculated requiring 14 C-serotonin release assay criteria to define positivity for
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HIT. All analyses were performed using SAS version 9.1 (Copyright 2005, SAS Institute, Cary,
NC) and LogXact Version 7.0 (Copyright 2005, Cytel Software Corporation).

Results
During the intervention time period, the CDSS alert occurred 41,922 times identifying 2,036
patients who had 2,338 inpatient admissions. The HIT CDSS was found to have a sensitivity of
87% and a specificity of 87%. The positive predictive value of the alert was 2.3% and the
negative predictive value was 99.9%. Of all patients receiving heparin during this time period,
13% developed platelet count decreases that triggered an alert for possible HIT. The 14Cserotonin release assay was positive in 81 patients during the control and 76 patients during the
intervention period (Table 1). Of those identified as positive, 47 of 81 in the control and 53 of
76 in the intervention periods also met the CDSS criteria of an active heparin order and
proportional platelet count decrease. Fifty-seven patients did not meet the CDSS criteria in the
combined control and intervention periods. Thirty-three of these patients were not on heparin
and either had a history of HIT or had been transferred from another institution. The remaining
24 patients did not have a platelet count decrease meeting the CDSS thresholds.

The analysis of the 24 patients that had exposure to heparin, but did not have a platelet count
decrease meeting the CDSS thresholds, revealed the following. One intervention patient had a
platelet count decrease meeting the CDSS thresholds, but was only on heparin drip for 2 hours
and the alert was never generated because it was within the 4 hour window. Of the remaining 23
patients, the platelet nadir percent decrease while on heparin compared with the previous highest
platelet count from the preceding 21 days, showed the following: 11 had less 20% decrease, 9
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had 20-30% decrease, 1 had 30-40% decrease and 2 had 40-50% decrease. The platelet percent
decrease off heparin when the HIT laboratory test was ordered compared with the previous
highest platelet count from the preceding 21 days, showed the following: 9 had less 20%
decrease, 2 had 20-30% decrease, 3 had 30-40% decrease, 2 had 40-50% decrease and 7 had
>50% decrease. Furthermore, 3 of these patients had a higher baseline platelet count beyond
21days but less than 90 days that would have cause a platelet count decrease meeting the CDSS
thresholds while on heparin.

Control and intervention patients with confirmed HIT were similar with regard to age, gender
and type of heparin product (Table 2). In the control period, the majority of diagnostic
interventions occurred due to a 50% platelet count decrease while in the intervention period more
alerts occurred following a 30% platelet count decrease (p=0.0002). The median interval
between the point of heparin discontinuation and the preceding alert threshold platelet count
criterion occurrence (Table 3) was 1.3 days in the control and 2.9 days in the intervention period
(p=0.04). The median interval between HIT laboratory test order and preceding platelet count
criterion was 2.3 days in the control and 3.0 days during the intervention period (p=0. 30).
Median direct thrombin inhibitor initiation occurred 19.3 days following platelet count criterion
in the control and 15.0 days in the intervention periods (p=0.45). Fifty-five percent of patients in
the control and 45% in the intervention period were discharged before a DTI was started.

We calculated hazard ratios comparing the intervention period to the control period overall and
by category of potential effect modifiers for each of the primary endpoints (Table 4). During the
intervention period, the time from platelet count criterion to heparin product discontinuation was
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significantly longer in the intervention period with a hazard ratio of 0.66 (95% CI 0.44-0.99), but
duration of heparin exposure and magnitude of platelet count decrease were found to be
confounders of this association. After adjustment for these factors, the hazard ratio was no
longer significant (0.79; 95% CI 0.50-1.24). The effect of the intervention on the time to first
HIT laboratory test drawn differed by service type (p=0.10).

Assessment of secondary endpoints revealed that 14C-serotonin release assay was ordered in
1.9% of admissions in the control (610 assays) and 2.5% in the intervention period (826 assays;
p<0.0001 The ELISA test was not available during the control period and an additional 330
ELISA tests were done in the intervention period. A total of 1156 HIT laboratory tests were done
in the interventional period on 674 unique hospitalizations. Of the 2338 inpatient admissions
that the CDSS alert occurred, 445 (19%) had at least one HIT lab test performed (64% 14Cserotonin release assay only, 1 % ELISA only, 35% both tests). The absolute number of
clinically documented thrombotic events among the confirmed HIT patients was small and
similar in control and intervention periods, except for an increase in superficial thrombosis
during the intervention period (p= 0.02, Table 5).

Discussion
We hypothesized that among clinicians caring for patients receiving heparin, the suspicion and
treatment of HIT should occur earlier following a defined fall in platelet count with the CDSS in
place than without. We found no clear alteration in promptness of ordering appropriate measures
(HIT laboratory test and DTI initiation), and an apparent delay in discontinuation of heparin
products. In addition, the secondary endpoints suggested an increased frequency of superficial
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thrombosis in the intervention group, although the numbers were small. Implementation of the
CDSS resulted in better ability to detect more subtle changes in platelet count (i.e. more
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serotonin release assays were ordered for a 30% decrease, and fewer for a 50% decrease, during
the intervention period. Despite this apparent increased sensitivity, there was no improvement in
time to therapeutic intervention. When an alert accompanied first occurrence of platelet count
criterion, clinicians appeared to delay discontinuation of heparin by an additional 1.6 days
compared to time to discontinuation without the alert. What accounts for this seemingly
paradoxical result? With a positive predictive value of only 2.3% and 41,922 alerts, physicians
may have become desensitized to alerted patients due to alert fatigue [22]. Modifications of the
CDSS are planned to decrease the number of alerts and improve the specificity of the program.

Review of those patients that had exposure to heparin, but did not have a platelet count decrease
meeting the CDSS thresholds, reveals that the baseline platelet count should be considered 90
days in past, not just 21 days used in our study. Also, after exposure to heparin was stopped the
platelet decrease continued in 52% of the patients to the CDSS thresholds when the HIT
laboratory test was ordered(7/23 by less 50% drop; 5/23 30% decrease with absolute platelet
count was less than 150,000 platelets/mm3 ). These findings will be used to determine
modifications to the CDSS.

Treatment of HIT should not be delayed awaiting laboratory confirmation but should be initiated
on clinical suspicion [11, 23]. The highest risk of thrombosis occurs between the time of
diagnosis of HIT and initiation of therapy [24]. In many institutions where the results of HIT
assays are not available daily, 14C-serotonin release assay and HIT antibodies by ELISA testing
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(platelet factor 4) tests may be only performed weekly. We measured only the time to ordering
of diagnostic testing and not time to receipt of results, but waiting for laboratory confirmation of
HIT could have delayed therapy by days. Nevertheless, a delay in laboratory results cannot
explain all of the findings. Physicians discontinued heparin as the first step of treating HIT but
failed reliably to start therapy immediately after stopping the offending agent. During both the
control and intervention periods the median time for initiation of HIT treatment in those patients
who received therapy was longer than 15 days, and more than 45% of patients were never started
on a DTI during their admission. It is clear that more education on HIT management is needed.
If an option were added to the CDSS that prompted the prescriber to order a DTI perhaps this
treatment delay would be prevented.

Analysis of effect modification and confounding provided some insight to the results. The effect
of the alert on time until laboratory test draw was dependent on specialty service, with surgeons
ordering appropriate laboratory tests earlier during the alert period. Perhaps surgeons were more
aware of platelet count trends. While there may be other effect modifiers, the confidence
intervals and p-values were too large to draw any firm conclusions. For example, time until
heparin discontinuation was dependent on alert type and duration of heparin exposure. If a
patient had been exposed to heparin for fewer than 5 days or had not had a dramatic platelet
decrease, then HIT may not have been high in a clinician’s differential, possibly resulting in a
delay in heparin discontinuation. Average duration of heparin therapy prior to the alert was
shorter during the intervention period, perhaps accounting for some of the longer time to
discontinuation. Furthermore, the criterion of a positive 14C-serotonin release assay to establish
a HIT positive patient identifies the most obvious HIT patients. Because HIT is often not an easy
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diagnosis, less obvious HIT patients may have been missed in this ‘first approach’ of the CDSS
but future iterations of the program will try to capture these ‘difficult’ patients.

Clinical decision support systems are used for a variety of conditions including preventative
medicine, medication dosing, and diagnosing medical conditions [18-20, 25-32]. Tools designed
to help with diagnosis have had variable impact on improvement of practitioner performance [19,
20, 25]. A CDSS related to HIT has been utilized at Mayo Clinic as part of a nurse driven
heparin nomogram system (HNS) [33]. The HNS incorporates patient specific information to
make dosage recommendations and order laboratory levels. In addition, this system has a
method of alerting nurses and physicians if the platelet count drops below 100,000
platelets/mm3, with a resulting notification rate of 6% for all patients monitored by the HNS
system. Our HIT CDSS had a notification rate of 13%; the difference may reflect our more
sensitive definition of HIT [4]. Evans and colleagues described a CDSS to help with the
appropriate selection of antibiotics. While this tool improved antibiotic decision-making, one
important finding was that the recommendations were not followed automatically [34].

Our goal was not to promulgate “cookbook medicine” but to give clinicians information to help
with diagnosis and choose appropriate therapy. The HIT CDSS did not lead to every patient
with thrombocytopenia undergoing evaluation for HIT with a laboratory test. Clinicians
apparently incorporated the alerts into their decision making to help with diagnosis, and did not
regard it as providing a definitive diagnosis.
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Although computerized reminders, alerts and other programs have been implemented with the
intention of improving physician compliance and patient care, the utility of this approach may be
highly dependent upon the specific details of implementation [35]. For example, if our alert had
incorporated educational components that gave the clinician options to discontinue heparin, order
a HIT laboratory test and start a DTI from the same screen as the platelet information, the results
may have been different. Kucher and colleagues describe an alert that gave information and
treatment options on the same screen for venous thromboembolism prophylaxis. This addition of
treatment options increased prophylaxis in comparison to a previous alert that only suggested
prophylaxis for patients [36]. For the HIT CDSS there must be methods to either exclude or
allow the clinician to “turn off” the alert for patients who do not have the condition and eliminate
extra alerts that contribute to alert desensitization and/or fatigue.

The conclusions of this study are limited by its retrospective design and by our decision to
include only the heparin antibody positive patients in the analysis. During the control period, it
would have been advantageous to attempt to identify platelet count criteria that went unnoticed,
as defined by failure to discontinue heparin, order HIT laboratory confirmation or substitute a
direct thrombin inhibitor, and compare these results with those during the intervention period.
Unfortunately, the data were not available in a format that permitted this type of query.
Moreover, had the alerts been followed concurrently it may have been possible to identify in
greater detail how clinicians used or disregarded the alerts and determine which patients should
have been evaluated for HIT. It is possible that prescribing practices may have changed between
the control and intervention periods, but we think this is unlikely. Because Thomas Jefferson
University Hospital had already in place an anti-thrombotic service, physicians may have had a
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high level of awareness of HIT making it difficult to improve upon this responsiveness.
Furthermore, both periods had a computer system that displayed labs in a trended fashion thus
making the intervention potentially redundant. In conclusion, our HIT CDSS was able to identify
potential HIT with good sensitivity and specificity, but the relatively low prevalence resulted in
many false positive alerts, perhaps desensitizing the clinicians to the alert. Although more
confirmatory laboratory testing was ordered during the intervention period, the time to treatment
or testing was not shortened by the alert. The CDSS was able to trigger an alert that resulted in
clinician response for more subtle changes in platelet count and following shorter durations of
heparin treatment, but we observed no decrease in thrombotic events. We plan modifications to
reduce the number of alerts and potentially improve patient outcomes. As clinical information
technology adoption gains more momentum, it becomes increasingly crucial to improve our
ability to design and implement truly effective decision support tools if we are to realize the
benefit that these technologies promise [37].

Acknowledgement:
Special thanks to TJUH Information Systems (Arlene Peters, Renee Brandell-Marino, Mary
McNichol, Michael Ekshtut, et al)
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Figure 1. Pop Up Alert
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Table 1. Demographics

Control

Intervention

Total Admissions
32,152
33,452
Admissions on UFH
11,111
11,154
Admissions on LMWH
4,806
4,952
Admissions on both
1,370
1,561
UFH & LMWH*
Total HIT Assays (14C610
826
serotonin release assay)
HIT ELISA Test
N/A
330
Assay Positive
81
76
Assay Positive and Meet
47
53
platelet count criterion
Assay Positive and NOT
34
23
Meet platelet count criterion
- Not on Heparin
18
15
- Platelet count above
16
8
Platelet count criterion
*Note: No patient was on UFH and LMWH at the same time but some were exposed to both
products during a single admission. Assay Positive refers to a positive 14C-serotonin release
assay.
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Table 2. Patients with HIT and Met Alert Criteria
Control (n=47)
Age*
Sex
Platelet
count
criterion
Type
Treatment
Time on
Heparin/
Enoxaparin
Service

Male
Female
50% drop
30% drop
with
platelet less
than 150
LMWH
UFH
Both
<=5 days
>5 days

p-value

63.4 (14.5)
25 (53.2)
22 (46.8)
35 (74.5)
12 (25.5)

Intervention
(n=53)
59.5 (12.7)
32 (60.4)
21 (39.6)
20 (37.7)
33 (62.3)

7 (14.9)
35 (74.5)
5 (10.6)
23 (48.9)
24 (51.1)

6 (11.3)
39 (73.6)
8 (15.1)
32 (60.4)
21 (39.6)

0.73

MED
25 (53.2)
37 (69.8)
SUR
22 (46.8)
16 (30.2)
* Age: Mean (standard deviation). All others: Frequency (percent)

0.12
0.47
0.0002

0.25
0.09
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Table 3. Evaluation of HIT CDSS
Outcome
(Times in days)

Control
N Median (95%
CI)*
47 1.3 (0.9-2.3)

Time from platelet count
criterion until
heparin/enoxaparin d/c
Time from platelet count 46 2.3 (1.6-3.6)
criterion until 1st HIT
laboratory test drawn†
Time from platelet count 47 19.3 (11.1-35.8)
criterion until direct
thrombin inhibitor
started
Time from platelet high 47 5.3 (4.7-6.8)
until alert platelet
*CI denotes confidence interval.
†

Intervention
N
Median (95%
CI)*
53 2.9 (1.8-3.2)

Log rank test
p-value

51

3.0 (2.0-4.0)

0.30

53

15.0 (7.327.3)

0.45

53

4.3 (2.6-6.4)

0.56

0.04

For the outcome of the time until the first HIT assay was ordered one patient in the control and

two patients in the intervention group were excluded due to the HIT assay being ordered prior to
the platelet count decreasing to CDSS thresholds.
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Table 4. Assessment of Effect Modification
Time from platelet
count criterion until
heparin discontinued
Clinically
Important
Factor
Unadjusted
Age

<55
≥55

Sex

Male
Female

Platelet
count
criterion
type

50%
drop

Time from platelet
count criterion until 1st
HIT laboratory test
drawn
Hazard
Interaction Hazard
Interaction
Ratio
p-value†
Ratio
p-value†
(95% CI)*
(95% CI)*
0.66 (0.440.81 (0.540.99)
1.21)
0.71 (0.33- 0.85
0.77 (0.36- 0.93
1.54)
1.68)
0.65 (0.410.80 (0.501.03)
1.29)
0.67 (0.39- 0.96
0.83 (0.49- 0.89
1.13)
1.42)
0.68 (0.370.79 (0.421.25)
1.46)
0.87 (0.50- 0.44
1.03 (0.59- 0.30
1.51)
1.80)

30%
0.62 (0.31drop
1.21)
with
platelet
less
than
150
Treatment LMWH 0.76 (0.25- 0.56
2.26)
UFH
0.59 (0.370.95)
Both
1.14 (0.373.52)
Time on
≤5
0.89 (0.50- 0.27
Heparin
days
1.60)
>5
0.56 (0.32days
0.98)
Service
MED
0.59 (0.31- 0.66
1.14)
SUR
0.71 (0.431.19)
*CI denotes confidence interval.

Time from platelet count
criterion until direct
thrombin inhibitor
started
Hazard
Interaction
Ratio
p-value†
(95% CI)*
1.13 (0.761.68)
2.51 (0.66- 0.24
9.57)
1.03 (0.551.95)
1.29 (0.61- 0.88
2.70)
1.18 (0.492.85)
1.33 (0.61- 0.92
2.92)

0.65 (0.331.28)

1.42 (0.484.24)

1.30 (0.43- 0.43
3.90)
0.68 (0.431.10)
1.23 (0.403.81)
0.79 (0.44- 0.87
1.43)
0.84 (0.491.47)
1.07 (0.63- 0.10
1.79)
0.52 (0.261.03)

2.31 (0.5110.49)
1.22 (0.622.39)
0.69 (0.143.42)
1.68 (0.694.05)
1.02 (0.492.15)
1.22 (0.592.54)
1.28 (0.523.19)

0.56

0.40

0.94
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†

The null hypothesis is that there are no significant differences between subgroups.

Table 5. Thrombotic Events

Deep Vein
Thrombosis
Superficial
Thrombosis
Pulmonary
Embolism
Myocardial
Infarction
Stroke

Control
(n=47)
8 (17.0%)

Intervention
(n=53)
13 (24.5%)

Adjusted Odds ratio
(95% CI)*
1.6 (0.54-4.9)

P
value
0.50

1 (2.1%)

7 (13.2%)

11.7 (1.3-581)

0.02

2 (4.3%)

2 (3.8%)

0.88 (0.06-12.7)

1.0

2 (4.3%)

4 (7.6%)

1.8 (0.25-21.1)

0.80

1 (2.1%)

4 (7.6%)

4.8 (0.47-49)

0.35

*CI denotes confidence interval.
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